1. Signaling Pathways
  2. GPCR/G Protein
    Neuronal Signaling
  3. mAChR
  4. mAChR3 Isoform

mAChR3

The M3 muscarinic acetylcholine receptor (M3-mAChR) is a G protein-coupled receptor that regulates diverse physiological processes, including smooth muscle contraction, glandular secretion, and cardiac function[1][2][3]. Mechanistically, M3-mAChR activation primarily signals through Gq proteins, inducing phospholipase C-β (PLC-β) activation, inositol trisphosphate (InsP3) generation, and intracellular Ca2+ release[4][5]. In airway smooth muscle cells, biased ligands such as PD 102807 mediate AMPK-dependent inhibition of mTORC1, attenuating TGF-β-induced hypercontractile phenotypes, whereas balanced agonists induce calcium-dependent AMPK signaling[2]. In cardiomyocytes, M3-mAChR stimulation delays cardiac aging by suppressing caspase-1/IL-1β signaling and modulating the miR-29b/BACE1 axis, reducing fibrosis and cell proliferation[6][7]. M3-mAChR is also implicated in tumorigenesis, facilitating epithelial-mesenchymal transition, perineural invasion, and angiogenesis via AKT and nitric oxide synthase pathways[8][9]. Compared with other muscarinic receptor isoforms, M3 exhibits unique coupling to multiple G protein families and distinctive regulatory motifs, such as NPxxY, which govern receptor signaling and multiprotein complex formation[1][10]. Functionally, selective agonists like choline and pilocarpine and inhibitors such as 4-DAMP allow experimental modulation of M3-mAChR activity, supporting disease modeling and therapeutic investigations in cardiovascular, respiratory, and oncological contexts[6][9][7][11]. Moreover, M3-mAChR forms microdomains with InsP3 receptors, creating localized Ca2+ signaling junctions critical for wave initiation in smooth muscle cells[5]. These properties distinguish M3-mAChR from other isoforms and facilitate its utility in mechanistic and pharmacological research.

References:

mAChR3 Related Products (99):

Cat. No. Product Name Effect Purity
  • HY-17366
    Clozapine N-oxide
    Agonist 99.98%
    Clozapine N-oxide is a major metabolite of Clozapine and a human muscarinic designer receptors (DREADDs) agonist. Clozapine N-oxide activates the DREADD receptor hM3Dq and hM4Di. Clozapine N-oxide can't cross the blood-brain barrier. Clozapine is a potent dopamine antagonist and also a potent and selective muscarinic M4 receptor (EC50=11 nM) agonist.
  • HY-42110
    Deschloroclozapine
    Agonist 99.93%
    Deschloroclozapine, a metabolite of Clozapine, is a highly potent muscarinic DREADDs agonist, with blood-brain barrier permeability. Deschloroclozapine binds to DREADD receptor subtypes hM3Dq and hM4Di with Ki of 6.3 and 4.2 nM, respectively. [11C]-Deschloroclozapine is developed as a promising PET tracer for DREADD imaging.
  • HY-B0726
    Pilocarpine Hydrochloride
    Agonist 99.98%
    Pilocarpine Hydrochloride is a potent M3-type muscarinic acetylcholine receptor (M3 muscarinic receptor) agonist.
  • HY-17366A
    Clozapine N-oxide dihydrochloride
    Agonist 99.74%
    Clozapine N-oxide dihydrochloride is a major metabolite of Clozapine and a human muscarinic designer receptors (DREADDs) agonist. Clozapine N-oxide dihydrochloride activates the DREADD receptor hM3Dq and hM4Di. Clozapine N-oxide dihydrochloride cannot cross the blood-brain barrier. Clozapine is a potent dopamine antagonist and also a potent and selective muscarinic M4 receptor (EC50=11 nM) agonist.
  • HY-B0726A
    Pilocarpine
    Agonist 99.89%
    Pilocarpine is a selective M3-type muscarinic acetylcholine receptor (M3 muscarinic receptor) agonist.
  • HY-183144
    Vedaclidine
    Modulator
    Vedaclidine is an orally active muscarinic acetylcholine receptor (mAChR) modulator with mixed receptor activity, which activates muscarinic M2 and M4 receptors and blocks muscarinic M1, M3 and M5 receptors. Vedaclidine exerts its activity through interaction with spinal M4 muscarinic receptors, and does not induce hypothermia or excessive salivation. Vedaclidine can be used in research related to pain, neuropathic pain and inflammatory pain states.
  • HY-131196
    M3 mAChR agonist 1
    Agonist
    M3 mAChR agonist 1 is an M3-preferring M3/M5 mAChR dual positive allosteric modulators (PAM). M3 mAChR agonist 1 shows excellent subtype selectivity over other subtypes of mAChRs including M1, M2, and M4 mAChRs. M3 mAChR agonist 1 increases the contraction of isolated rat bladder strips by modulating the M3 muscarinic acetylcholine receptor, leading to enhanced signaling pathways. M3 mAChR agonist 1 can be used for the research of endocrinology.
  • HY-137388
    p-F-HHSiD
    Antagonist
    p-F-HHSiD (p-Fluorohexahydrosiladifenidol) is a potent and selective M3 mAChR antagonist. p-F-HHSiD has antagonistic effects on other subtypes of the M receptor and the alpha1-adrenoceptor. p-F-HHSiD can be used for the researches of cancer, metabolic, neurological and cardiovascular disease such as, colon cancer, Alzheimer’s disease and diabetes.
  • HY-A0083
    Methacholine chloride
    Agonist ≥98.0%
    Methacholine (Acetyl-β-methylcholine) choride is a potent muscarinic-3 (M3) agonist. Methacholine choride acts directly on acetylcholine receptors on smooth muscle causing bronchoconstriction and airway narrowing. Methacholine choride shows a high sensitivity to identify bronchial hyperresponsiveness (BHR). Methacholine choride can be used to measure airway hyperresponsiveness (AHR) as a diagnostic aid in the assessment of individuals with asthma-like symptoms and normal resting expiratory flow rates.
  • HY-A0012
    Darifenacin hydrobromide
    Antagonist 99.78%
    Darifenacin (UK-88525) hydrobromide is a selective and orally active M3 muscarinic receptor (M3R) antagonist with a pKi of 8.9. Darifenacin hydrobromide binds >20-fold more specifically to M3R than to other muscarinic receptors. Darifenacin hydrobromide can be used in the study of urinary incontinence and other symptoms of overactive bladder. Darifenacin hydrobromide inhibits tumor growth in colorectal cancer cells and has anti-tumor effects.
  • HY-A0033
    Darifenacin
    Antagonist 99.81%
    Darifenacin (UK-88525) is a selective and orally active M3 muscarinic receptor (M3R) antagonist with a pKi of 8.9. Darifenacin binds >20-fold more specifically to M3R than to other muscarinic receptors. Darifenacin can be used in the study of urinary incontinence and other symptoms of overactive bladder. Darifenacin inhibits tumor growth in colorectal cancer cells and has anti-tumor effects.
  • HY-17360
    Tiotropium Bromide
    Antagonist 99.91%
    Tiotropium bromide (BA-679 BR) is a long-acting anticholinergic bronchodilator. Tiotropium bromide blocks the action of acetylcholine at muscarinic M1, M2, and M3 receptors, prevents bronchoconstriction, and dilates bronchial airways. Tiotropium bromide is applicable to research related to chronic obstructive pulmonary disease and asthma.
  • HY-107647
    (S)-(+)-Dimethindene maleate
    Antagonist 99.80%
    (S)-(+)-Dimethindene maleate, an enantiomer, is a potent M2-selective muscarinic receptor antagonist (pA2 = 7.86/7.74; pKi = 7.78). (S)-(+)-Dimethindene maleate shows lower affinities for the muscarinic M1 (pA2 = 6.83/6.36; pKi = 7.08), the M3 (pA2 = 6.92/6.96; pKi = 6.70) and the M4 receptors (pKi = 7.00), respectively. (S)-(+)-Dimethindene maleate also is a histamine H1 receptor antagonist (pA2 = 7.48).
  • HY-100958
    4-DAMP
    Antagonist 99.96%
    4-DAMP (4-DAMP methiodide) is a potent and selective antagonist of M3 receptors and also has a high affinity for the closely-related M5 receptors. 4-DAMP combined with 5-Fluorouracil (5-Fu) (HY-90006) could significantly reduce the cell viability and enhance apoptosis in MKN45 and BGC823 gastric cancer cells. 4-DAMP inhibits lipopolysaccharide (LPS)- and tobacco-induced pulmonary inflammation and reduces mucin 5AC (MUC5AC), oligomeric mucus/gel-forming secretion.
  • HY-122743
    Iperoxo
    Agonist 99.48%
    Iperoxo is a potent superagonist of muscarinic acetylcholine receptor (mAChR) that activates M1, M2 and M3 receptors with pEC50 of 9.87, 10.1 and 9.78. Iperoxo can be used for direct probing activation-related conformational transitions of muscarinic receptors when labeled with tritium.
  • HY-B0406A
    Bethanechol chloride
    Agonist 99.56%
    Bethanechol chloride (Carbamyl-β-methylcholine chloride), a parasympathomimetic agent, is a mAChR agonist that exerts its effects via directly stimulating the mAChR (M1, M2, M3, M4, and M5) of the parasympathetic nervous system.
  • HY-70020B
    Cevimeline hydrochloride
    Agonist 98.74%
    Cevimeline hydrochloride (AF102B hydrochloride) is a quinuclidine derivative of acetylcholine and a selective and orally active muscarinic M1 and M3 receptor agonist. Cevimeline hydrochloride stimulates secretion by the salivary glands and can be used as a sialogogue for xerostomia. Cevimeline hydrochloride can cross the blood-brain barrier (BBB).
  • HY-100234
    DREADD agonist 21
    Agonist 99.46%
    DREADD agonist 21 is a potent human muscarinic acetylcholine M3 receptors (hM3Dq) agonist (EC50=1.7 nM).
  • HY-100234A
    DREADD agonist 21 dihydrochloride
    Agonist 98.94%
    DREADD agonist 21 dihydrochloride is a potent human muscarinic acetylcholine M3 receptors (hM3Dq) agonist (EC50=1.7 nM).
  • HY-B1006
    Pilocarpine nitrate
    Agonist 99.83%
    Pilocarpine nitrate is a potent M3-type muscarinic acetylcholine receptor (M3 muscarinic receptor) agonist.